OLIVE PHARMASCIENCE LIMITED
OLIVE PHARMASCIENCE LIMITED is a drug establishment in Daman, India, registered with the US FDA under FEI 3009681646. Its registered operations are: Drug manufacture. 3 EU/UK GMP certificates are matched to this site, 2 inspected within the last three years; 1 has since been withdrawn by the issuing authority. FDA has published 2 inspection outcomes for this FEI; the most recent, ended 31 Mar 2017, was classified voluntary action indicated (VAI).
Sources: FDA Drug Establishments Current Registration Site (checked 16 Nov 2026); FDA Data Dashboard (inspections); EudraGMDP; MHRA GMDP. Methodology
Cite as: PharmaTek, “OLIVE PHARMASCIENCE LIMITED: FDA registration, inspection and GMP record (FEI 3009681646)”, record as of 16 Nov 2026, pharmatek.co.uk/manufacturing-sites/olive-pharmascience-limited-daman-3009681646
Registered operations
Business operations this establishment declares in its FDA registration. Registration is not an approval and says nothing about EU or UK GMP status.
GMP documents matched to this site (3)
| Document | Authority | Inspection | Source |
|---|---|---|---|
FT046/MH/001/2025 GMP certificate | Competent authority of Portugal | 8 Mar 2024 within 3-year review window | EudraGMDP |
FT046/MH/001/2024 GMP certificate | Competent authority of Portugal | 8 Mar 2024 within 3-year review window | EudraGMDP |
FT046/001/2018 GMP certificate | Competent authority of Portugal | 10 Nov 2017 Withdrawn by the authority on 1 Aug 2025 Register note: Replaced by GMP certificate no. FT046/001/2018 ref key 168341 | EudraGMDP |
A GMP document is matched to this site when its address names the site's street and its city or postcode. In our latest internal review 59 of 60 sampled matches were the right site (not yet independently reviewed; measured match quality). Check the certificate's own address before relying on it. The three-year review window is the EMA guideline default after an inspection, not an official expiry date.
FDA inspection outcomes (2)
| Inspection ended | Outcome | Programme area | Citations posted |
|---|---|---|---|
| 31 Mar 2017 | VAI · Voluntary action indicated | Drug Quality Assurance | No |
| 20 Sept 2012 | VAI · Voluntary action indicated | Drug Quality Assurance | Yes |
FDA Data Dashboard, joined on the FEI. NAI: no objectionable conditions found. VAI: objectionable conditions found, but not serious enough for regulatory action. OAI: regulatory or administrative action recommended. A classification describes one inspection on one date; FDA publishes it only once final and does not publish every inspection. FDA firm profile
Form 483 observations (3)
Inspection ended 20 Sept 2012: 3 observations
- 21 CFR 211.100(b) SOPs not followed / documented
- 21 CFR 211.67(a) Cleaning / Sanitizing / Maintenance
- 21 CFR 211.100(a) Absence of Written Procedures
FDA Data Dashboard (inspection citations), joined on the FEI. Each line is the regulation cited and FDA's short description, not the full observation text. A Form 483 lists an investigator's observations at the close of an inspection; it is not a final agency determination, and FDA does not publish citations for every inspection.
What this page does not show
- Which substances are made here: DMFs and CEPs are filed by organisations, not sites, so we do not link substances to this site.
- Capacity, scale, price or current availability: no regulator publishes these.
- The full text of a Form 483 or warning letter: FDA's dashboard gives the regulation cited and a short description only.
Is this OLIVE HEALTHCARE?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.